Mirtazapin Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. GNH USA supplies Mirtazapin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts within the central nervous system to alleviate depressive symptoms and is approved for use in major depressive disorder. - Major depressive disorder: reduces depressive mood, improves sleep and appetite in adults. - Depressive episodes in adults: alleviates core symptoms of sadness, loss of interest and low energy. - Depression with insomnia: helps restore sleep patterns while treating depressive signs.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Severe hypotension - Hepatic dysfunction - Seizures (rare)

Before initiating therapy with Mirtazapin Sandoz, several safety considerations should be reviewed. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; consider alternative therapy. - Elderly patients: monitor for excessive sedation and fall risk. - Concomitant CNS depressants: may potentiate sedation and respiratory depression. - History of bipolar disorder: risk of mood elevation or rapid cycling. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapin Sandoz can interact with other medicines, requiring careful assessment of the interaction potential.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome and hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Anticholinergic agents: increased anticholinergic burden. - Warfarin: potential alteration of INR, requiring closer monitoring.